Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results
October 21, 2015 1:42 PM EDTLeerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported a 3Q beat on all top and bottom line levels. 3Q sales of 2.78 bn. vs. consensus estimates of $2.6B, 3Q non-GAAP EPS of 4.48 vs.... More
Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat
October 21, 2015 1:36 PM EDTCowen reiterated an Outperform rating and $368.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported strong Q3 non-GAAP EPS of $4.48 vs. consensus of $3.84E, on revenue of $2.8B.
Analyst Eric Schmidt commented, "BIIB reported Q3 revenue and earnings well above... More
RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 Results
October 21, 2015 9:22 AM EDTRBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $450. Earlier Biogen reported Q3 results including a corporate restructuring and headcount reduction. In the view of analyst Michael J. Yee, this was relative good news against very low... More
Biogen's (BIIB) Phase 3 ASCEND Trial Missed Primary, Secondary Endpoints
October 21, 2015 7:32 AM EDTThe Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile.
ASCEND evaluated the efficacy and... More
Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS Outlook
October 21, 2015 7:31 AM EDTBiogen (NASDAQ: BIIB) reported Q3 EPS of $4.48, $0.68 better than the analyst estimate of $3.80. Revenue for the quarter came in at $2.39 billion versus the consensus estimate of $2.65 billion.
Corporate Restructuring
The Company plans to substantially complete the majority of the 11% reduction of its global workforce by the end of 2015. The Company is in the process of notifying employees affected by the restructuring, and... More
